Observational analysis found arginine auxotrophy in acute lymphoblastic leukemia, suggesting biomarkers like ASS1 may refine personalized therapy with asparaginase and pegargiminase.
Key Points
Apoptosis was significantly induced in ASS1-low acute lymphoblastic leukemia cell lines, confirming an arginine auxotrophic state.
Transcriptomic and genomic data from 800 patients revealed biomarkers linked to arginine auxotrophy in Philadelphia-chromosome positive cases.
Pre-clinical evaluation showed that pegargiminase combined with dasatinib is effective against TKI-resistant leukemia models.
Findings suggest that targeting arginine auxotrophy may lead to novel, chemotherapy-light approaches in treating acute lymphoblastic leukemia.